Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > BUSINESS
BUSINESS
- Mylan Applies for Ciclosporin for Additional Indication Based on Data from Public Domain
December 11, 2012
- Teva Pharma Halts Sales of Pinatos Due to GMP Non-Compliance of South Korean Supplier
December 10, 2012
- JT Submits NDA for Anti-HIV Combination Drug, 1st NDA for Compound It Discovered
December 10, 2012
- US FDA Accepts NDA for Tacrolimus Extended-Release Capsules: Astellas
December 10, 2012
- Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
- IP High Court Reverses JPO Ruling on Lipitor Patent
December 7, 2012
- With Spiriva Combination Product in PIII, BI Not Fear Competition in COPD Market: Chairman Barner
December 7, 2012
- Ex-JPMA Secretary General Expresses Hope for Globalization of Domestic Pharma Industry: JPLA Seminar
December 7, 2012
- ARB Market Nearing Its Limit; No More Growth in the Second Half?
December 7, 2012
- MSD Submits NDA for Novel Insomnia Treatment Suvorexant
December 6, 2012
- Lantus Shows Low Incidence of Hypoglycemia in Combination Use with OHA: Sanofi
December 5, 2012
- Astellas Initiates Patient Enrollment in PII Trial of Tivozanib for Triple Negative Breast Cancer
December 5, 2012
- US Merck Initiates Multinational PII/III Study for BACE Inhibitor for Alzheimer’s Disease
December 5, 2012
- Pediatric NDA for AcipHex Granted Priority Review by US FDA: Eisai
December 4, 2012
- Hospira Applies for Irinotecan Generic for Pediatric Malignant Solid Tumors Based on Data from the Public Domain
December 4, 2012
- Novartis Concludes Comarketing Agreement with Taisho for SGLT-2 Inhibitor Luseogliflozin
December 4, 2012
- Sanwa Kagaku, Kowa Launch DPP-4 Inhibitor Suiny on November 30
December 3, 2012
- Novartis AG Receives First Approval for Cell-Culture Influenza Vaccine in the US
December 3, 2012
- Fast-growing Plavix Could Become Japan’s No. 1 Ethical Drug by Next Year
December 3, 2012
- US FDA Accepts NDA Filing for Tivozanib: Astellas
November 30, 2012
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…